A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1489 participants.

Also called NCT04915729

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,489 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04915729
Other papers using this trial's data
  • Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial JAMA, 2024-11-05 DOI, PubMed 39264623, PMC11393753 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04915729. Randomized; single masking; primary purpose treatment. Start 2021-06-22 (actual); primary completion 2023-10-08 (actual). Results posted on 2024-12-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity
Acronym
ORIGINAL
Condition
Stroke
Intervention (Drug)
tenecteplase
Intervention (Drug)
alteplase
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct04915729
Content hash
8fc81e62ffb30b28a1e6e5051a22f6eeeac9e1d4fe07a4ad35895e25d45d12f3